UniProt P40337
Von Hippel-Lindau disease tumor suppressor (P40337)
Von Hippel-Lindau disease tumor suppressor (UniProt P40337): 123 experimental structures and 1 predicted model on GenesisL1, 41 ligands bound, 178 pockets. Binding sites, druggability and experiment against prediction (TM-score)…
- UniProt
- P40337
- Protein
- Von Hippel-Lindau disease tumor suppressor
- Experimental structures
- 123
- Predicted models
- 1
- Ligands
- 41
- Pockets
- 178 · 30 records with a druggable one
Structures
124 records of P40337 in the MolNFT archive: 123 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1LM8 | Structure of a HIF-1a-pVHL-ElonginB-ElonginC Complex | x-ray diffraction | V | — | — |
| 1LM8 | Structure of a hif-1A-pvhl-elonginb-elonginc complex | x-ray diffraction | V | — | — |
| 1LQB | Crystal structure of a hydroxylated HIF-1 alpha peptide bound to the pVHL/elongin-C/elongin-B… | x-ray diffraction | C | — | — |
| 1LQB | Crystal structure of a hydroxylated hif-1 alpha peptide bound to the PVHL/ELONGIN-C/ELONGIN-B… | x-ray diffraction | C | — | — |
| 1VCB | The vhl-elonginc-elonginb structure | x-ray diffraction | C, F, I, L | — | — |
| 1VCB | The vhl-elonginc-elonginb structure | x-ray diffraction | C, F, I, L | — | — |
| 3ZRC | pVHL54-213-EloB-EloC complex (4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5-YL)ACETYL]-N-[4-(1,3-OXAZOL-5-YL)… | x-ray diffraction | C, F, I, L | — | — |
| 3ZRC | PVHL54-213-elob-eloc complex (4R)-4-hydroxy-1-[(3-methylisoxazol-5… | x-ray diffraction | C, F, I, L | — | — |
| 3ZRF | pVHL54-213-EloB-EloC complex_apo | x-ray diffraction | C, F, I, L | — | — |
| 3ZRF | PVHL54-213-elob-eloc COMPLEX_APO | x-ray diffraction | C, F, I, L | — | — |
| 3ZTC | pVHL54-213-EloB-EloC complex _ (2S,4R)-N-((1,1'-biphenyl)-4-ylmethyl)… | x-ray diffraction | C, F, I, L | — | — |
| 3ZTC | PVHL54-213-elob-eloc complex _ (2S,4R)-N-((1,1'-biphenyl)-4-ylmethyl)… | x-ray diffraction | C, F, I, L | — | — |
| 3ZTD | pVHL54-213-EloB-EloC complex _ methyl 4-(((2S,4R)-4-hydroxy-1-(2-(3… | x-ray diffraction | C, F, I, L | — | — |
| 3ZTD | PVHL54-213-elob-eloc complex _ methyl 4-(((2S,4R)-4-hydroxy… | x-ray diffraction | C, F, I, L | — | — |
| 3ZUN | pVHL54-213-EloB-EloC complex_(2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol… | x-ray diffraction | C, F, I, L | — | — |
| 3ZUN | PVHL54-213-elob-eloc COMPLEX_(2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol… | x-ray diffraction | C, F, I, L | — | — |
| 4AJY | von Hippel-Lindau protein-ElonginB-ElonginC complex, bound to Hif1- alpha peptide | x-ray diffraction | V | — | — |
| 4AJY | Von hippel-lindau protein-elonginb-elonginc complex, bound to HIF1- alpha peptide | x-ray diffraction | V | — | — |
| 4AWJ | pVHL:EloB:EloC complex, in complex with capped Hydroxyproline | x-ray diffraction | C, F, I, L | — | — |
| 4AWJ | PVHL:ELOB:ELOC complex, in complex with capped hydroxyproline | x-ray diffraction | C, F, I, L | — | — |
| 4B95 | pVHL-EloB-EloB-EloC complex_(2S,4R)-1-(2-chlorophenyl)carbonyl-N-[(4-chlorophenyl)methyl]-4-oxidanyl… | x-ray diffraction | C, F, I, L | — | — |
| 4B95 | Pvhl-elob-elob-eloc COMPLEX_(2S,4R)-1-(2-CHLOROPHENYL)CARBONYL-N-[(4… | x-ray diffraction | C, F, I, L | — | — |
| 4B9K | pVHL-ELOB-ELOC complex_(2S,4R)-1-(3-amino-2-methylbenzoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benz… | x-ray diffraction | C, F, I, L | — | — |
| 4B9K | Pvhl-elob-eloc COMPLEX_(2S,4R)-1-(3-amino-2-methylbenzoyl)-4… | x-ray diffraction | C, F, I, L | — | — |
| 4BKS | von Hippel Lindau protein:ElonginB:ElonginC complex, in complex with… | x-ray diffraction | C, F, I, L | — | — |
| 4BKS | Von hippel lindau PROTEIN:ELONGINB:ELONGINC complex, in complex with… | x-ray diffraction | C, F, I, L | — | — |
| 4BKT | von Hippel Lindau protein:ElonginB:ElonginC complex, in complex with… | x-ray diffraction | C, F, I, L | — | — |
| 4BKT | Von hippel lindau PROTEIN:ELONGINB:ELONGINC complex, in complex with… | x-ray diffraction | C, F, I, L | — | — |
| 4W9C | pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)p… | x-ray diffraction | C, F, I, L | — | — |
| 4W9C | PVHL:ELOB:ELOC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4… | x-ray diffraction | C, F, I, L | — | — |
| 4W9D | pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methyloxazol-5-yl)… | x-ray diffraction | C, F, I, L | — | — |
| 4W9D | PVHL:ELOB:ELOC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4… | x-ray diffraction | C, F, I, L | — | — |
| 4W9E | pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(thiazol-5-yl)benzyl)… | x-ray diffraction | C, F, I, L | — | — |
| 4W9E | PVHL:ELOB:ELOC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4… | x-ray diffraction | C, F, I, L | — | — |
| 4W9F | pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl… | x-ray diffraction | C, F, I, L | — | — |
| 4W9F | PVHL:ELOB:ELOC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4… | x-ray diffraction | C, F, I, L | — | — |
| 4W9G | pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(3-methyl-4-(thiazol-5-y… | x-ray diffraction | C, F, I, L | — | — |
| 4W9G | PVHL:ELOB:ELOC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4… | x-ray diffraction | C, F, I, L | — | — |
| 4W9H | pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-acetamido-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-me… | x-ray diffraction | C, F, I, L | — | — |
| 4W9H | PVHL:ELOB:ELOC in complex with (2S,4R)-1-((S)-2-acetamido-3,3… | x-ray diffraction | C, F, I, L | — | — |
| 4W9I | pVHL:EloB:EloC in complex with (2S,4R)-1-((2S,4R)-1-acetyl-4-hydroxypyrrolidine-2-carbonyl)-4-hydrox… | x-ray diffraction | C, F, I, L | — | — |
| 4W9I | PVHL:ELOB:ELOC in complex with (2S,4R)-1-((2S,4R)-1-acetyl-4… | x-ray diffraction | C, F, I, L | — | — |
| 4W9J | pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-((S)-2-acetamido-4-methylpentanamido)-3,3-dimethylbu… | x-ray diffraction | C, F, I, L | — | — |
| 4W9J | PVHL:ELOB:ELOC in complex with (2S,4R)-1-((S)-2-((S)-2-acetamido-4… | x-ray diffraction | C, F, I, L | — | — |
| 4W9K | pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-((S)-2-acetamido-3-phenylpropanamido)-3,3-dimethylbu… | x-ray diffraction | C, F, I, L | — | — |
| 4W9K | PVHL:ELOB:ELOC in complex with (2S,4R)-1-((S)-2-((S)-2-acetamido-3… | x-ray diffraction | C, F, I, L | — | — |
| 4W9L | pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-((S)-2-acetamido-3,3-dimethylbutanamido)-3,3-dimethy… | x-ray diffraction | C, F, I, L | — | — |
| 4W9L | PVHL:ELOB:ELOC in complex with (2S,4R)-1-((S)-2-((S)-2-acetamido-3,3… | x-ray diffraction | C, F, I, L | — | — |
| 4WQO | Structure of vhl-elob-eloc-CUL2 | x-ray diffraction | A | — | — |
| 5LLI | pVHL:EloB:EloC in complex with VH298 | x-ray diffraction | C, F, I, L | — | — |
| 5LLI | PVHL:ELOB:ELOC in complex with VH298 | x-ray diffraction | C, F, I, L | — | — |
| 5N4W | Crystal structure of the Cul2-Rbx1-EloBC-VHL ubiquitin ligase complex | x-ray diffraction | V | — | 3 (best 0.53) |
| 5N4W | Crystal structure of the CUL2-RBX1-elobc-vhl ubiquitin ligase complex | x-ray diffraction | V | — | — |
| 5NVV | PVHL:ELOB:ELOC in complex with (2S,4R)-4-hydroxy-1-((S)-2-(2… | x-ray diffraction | C, F, I, L | — | — |
| 5NVW | pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(cyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hy… | x-ray diffraction | C, F, I, L | 9BW | 7 (best 0.60) |
| 5NVW | PVHL:ELOB:ELOC in complex with (2S,4R)-1-((S)-2- (cyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-h… | x-ray diffraction | C, F, I, L | — | — |
| 5NVX | pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutano… | x-ray diffraction | C, F, I, L | 4YY | 7 (best 0.61) |
| 5NVX | PVHL:ELOB:ELOC in complex with (2S,4R)-1-((S)-2-(1… | x-ray diffraction | C, F, I, L | — | — |
| 5NVY | pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-acetamidopropanoyl)-4-hydroxy-N-(4-(4-methylthiazol… | x-ray diffraction | C, F, I, L | 9B5 | 8 (best 0.58) |
| 5NVY | PVHL:ELOB:ELOC in complex with (2S,4R)-1-((S)-2-acetamidopropanoyl)-4… | x-ray diffraction | C, F, I, L | — | — |
64 records more on the page itself.
Ligands
- F4K · (4-pyrrol-1-ylphenyl)methanol · in 3 records
- FWZ · (2~{S},4~{R})-~{N}-[[2-[2-[4-[[4-[3-azanyl-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]methyl]phenyl]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 3 records
- 759 · (2~{S},4~{R})-1-[(2~{S})-2-[2-[2-[2-[2-[2-[(9~{S})-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]ethanoylamino]ethoxy]ethoxy]ethoxy]ethanoylamino]-3,3-dimethyl-butanoyl]-~{N}-[[4-(4-methyl-2,3-dihydro-1,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 2 records
- FX8 · (2~{S},4~{R})-~{N}-[[2-[2-[2-[2-[4-[3-azanyl-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 2 records
- NA · Sodium ion · in 2 records
- Q3X · ~{N}-[5-[4-[2-[2-[2-[2-[3-[[3,3-dimethyl-1-[(2~{S},4~{R})-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamoyl]-4-oxidanyl-pyrrolidin-1-yl]-1-oxidanylidene-butan-2-yl]amino]-3-oxidanylidene-propoxy]ethoxy]ethoxy]ethoxy]ethylcarbamoyl]phenyl]-2-(4-methylpiperazin-1-yl)phenyl]-6-oxidanylidene-4-(trifluoromethyl)-3~{H}-pyridine-3-carboxamide · in 2 records
- SCN · Thiocyanate ion · in 2 records
- WEP · N-[11-({7-(3,5-difluoropyridin-2-yl)-2-methyl-10-[(methylsulfonyl)methyl]-3-oxo-3,4,6,7-tetrahydro-2H-2,4,7-triazadibenzo[cd,f]azulene-9-carbonyl}amino) undecanoyl]-3-methyl-L-valyl-(4R)-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}-L-prolinamide · in 2 records
- 4YY · N-[(1-fluorocyclopropyl)carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-N-[4-(4-methyl-1,3-thiazol-5-yl)benzyl]-L-prolinamide · in 1 record
- 87A · N-(1-fluorocyclopropane-1-carbonyl)-3-methyl-L-valyl-(4R)-N-{[2-{2-[4-({4-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl}methyl)phenoxy]ethoxy}-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}-4-hydroxy-L-prolinamide · in 1 record
- 8KH · N-[5-[4-[[5-[[(2S)-3,3-dimethyl-1-[(2S,4R)-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamoyl]-4-oxidanyl-pyrrolidin-1-yl]-1-oxidanylidene-butan-2-yl]amino]-5-oxidanylidene-pentyl]carbamoyl]phenyl]-2-(4-methylpiperazin-1-yl)phenyl]-6-oxidanylidene-4-(trifluoromethyl)-1H-pyridine-3-carboxamide · in 1 record
- 9B5 · (2~{S},4~{R})-1-[(2~{S})-2-acetamidopropanoyl]-~{N}-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 1 record
- 9B8 · (2~{S},4~{R})-1-[(2~{S})-3,3-dimethyl-2-(oxetan-3-ylcarbonylamino)butanoyl]-~{N}-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 1 record
- 9BH · (2~{S},4~{R})-1-[(2~{S})-2-(cyclobutylcarbonylamino)-3,3-dimethyl-butanoyl]-~{N}-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 1 record
- 9BN · (2~{S},4~{R})-1-[(2~{S})-2-[(1-ethanoylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-~{N}-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 1 record
- 9BW · (2~{S},4~{R})-1-[(2~{S})-2-(cyclopropylcarbonylamino)-3,3-dimethyl-butanoyl]-~{N}-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 1 record
- A1H9F · (2S,4R)-1-[(2R)-2-[(1-fluoranylcyclopropyl)carbonylamino]-3-methyl-3-[[trans-4-(morpholin-4-ylmethyl)cyclohexyl]methylsulfanyl]butanoyl]-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 1 record
- A1L2C · 4-(hydroxymethyl)-7-oxidanyl-chromen-2-one · in 1 record
- CAD · Cacodylic acid · in 1 record
- DV2 · ~{N}-[(2~{S})-1-[(2~{S},4~{R})-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamothioyl]-4-oxidanyl-pyrrolidin-1-yl]-1-oxidanylidene-propan-2-yl]ethanamide · in 1 record
- DV5 · (2~{S},4~{R})-1-[(2~{S})-2-acetamidopropanethioyl]-~{N}-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 1 record
- DV8 · ~{N}-[(2~{S})-1-[(2~{S},4~{R})-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamothioyl]-4-oxidanyl-pyrrolidin-1-yl]-1-sulfanylidene-propan-2-yl]ethanamide · in 1 record
- EXH · (2~{R},3~{R},4~{S})-1-[(2~{S})-2-acetamido-3,3-dimethyl-butanoyl]-3-fluoranyl-~{N}-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 1 record
- IFF · (2~{S},4~{R})-~{N}-[(1~{S})-4-[4-(4-bromanyl-7-cyclopentyl-5-oxidanylidene-benzimidazolo[1,2-a]quinazolin-9-yl)piperidin-1-yl]-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]butyl]-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 1 record
- IFJ · (2~{S},4~{R})-~{N}-[(1~{R})-2-[(2~{R})-1-[4-(4-bromanyl-7-cyclopentyl-5-oxidanylidene-benzimidazolo[1,2-a]quinazolin-9-yl)piperidin-1-yl]propan-2-yl]oxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]-1-[(2~{S})-2-[[1-(dimethylamino)cyclopropyl]carbonylamino]-3,3-dimethyl-butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 1 record
- IOD · Iodide ion · in 1 record
- LFE · ~{N}-[(5~{S},7~{R},11~{S},23~{S})-11-~{tert}-butyl-34-(4-methyl-1,3-thiazol-5-yl)-7-oxidanyl-4,10,13-tris(oxidanylidene)-15,18,21,25,28,31-hexaoxa-3,9,12-triazatricyclo[30.4.0.0^{5,9}]hexatriaconta-1(32),33, 35-trien-23-yl]-2-[(7~{S},9~{S})-7-(4-chlorophenyl)-4, 5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,10,12-tetraen-9-yl]ethanamide · in 1 record
- PO4 · Phosphate ion · in 1 record
- QE9 · (2~{S},4~{R})-~{N}-[[2-(2-methoxyethoxy)-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 1 record
- QFF · (2~{S},4~{R})-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-~{N}-[4-(4-methyl-1,3-thiazol-5-yl)phenoxy]-4-oxidanyl-pyrrolidine-2-carboxamide · in 1 record
Experiment against prediction
- 4B95 chain F against the predicted model P40337: TM-score 0.99, RMSD 0.35 Å
- 8ZV8 chain C against the predicted model P40337: TM-score 0.99, RMSD 0.34 Å
- 8BDM chain I against the predicted model P40337: TM-score 0.99, RMSD 0.38 Å
- 8ZV8 chain F against the predicted model P40337: TM-score 0.99, RMSD 0.38 Å
- 6GMR chain V against the predicted model P40337: TM-score 0.99, RMSD 0.40 Å
- 8ZV8 chain L against the predicted model P40337: TM-score 0.99, RMSD 0.40 Å
- 4BKT chain F against the predicted model P40337: TM-score 0.99, RMSD 0.41 Å
- 8ZV8 chain I against the predicted model P40337: TM-score 0.99, RMSD 0.40 Å
- 8BDM chain F against the predicted model P40337: TM-score 0.99, RMSD 0.42 Å
- 4BKT chain C against the predicted model P40337: TM-score 0.99, RMSD 0.44 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.